Published in Infect Immun on March 01, 1996
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev (2000) 3.05
In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother (1998) 1.19
Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J (2000) 1.19
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother (1999) 1.12
In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 1.11
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother (2006) 1.04
Phospholipase A2 and phospholipase B activities in fungi. Biochim Biophys Acta (2006) 0.99
PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates. Appl Environ Microbiol (2003) 0.93
The Penicillium chrysogenum extracellular proteome. Conversion from a food-rotting strain to a versatile cell factory for white biotechnology. Mol Cell Proteomics (2010) 0.91
Polarized response of endothelial cells to invasion by Aspergillus fumigatus. Cell Microbiol (2008) 0.90
Disruption of the phospholipase D gene attenuates the virulence of Aspergillus fumigatus. Infect Immun (2011) 0.86
Interaction of serotonin with Candida albicans selectively attenuates fungal virulence in vitro. Int J Antimicrob Agents (2005) 0.77
Effect of phosphatidylcholine on the level expression of plc genes of Aspergillus fumigatus by real time PCR method and investigation of these genes using bioinformatics analysis. Iran J Microbiol (2014) 0.75
Effect of phosphatidylcholine on pld gene expression level of Aspergillus fumigatus by the real time PCR method and investigations of these genes using bioinformatics analysis. Iran J Microbiol (2012) 0.75
Interactions of Aspergillus fumigatus Conidia with Airway Epithelial Cells: A Critical Review. Front Microbiol (2016) 0.75
Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta (1994) 3.42
Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect Immun (1995) 2.75
Purification and characterization of an extracellular 29-kilodalton phospholipase C from Listeria monocytogenes. Infect Immun (1991) 2.41
Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase C) of Clostridium perfringens. Infect Immun (1989) 1.97
Correlation of elastase production by some strains of Aspergillus fumigatus with ability to cause pulmonary invasive aspergillosis in mice. Infect Immun (1984) 1.97
Immunosuppression in vitro by a metabolite of a human pathogenic fungus. Proc Natl Acad Sci U S A (1984) 1.74
The putative phosphoinositide-specific phospholipase C gene, PLC1, of the yeast Saccharomyces cerevisiae is important for cell growth. Proc Natl Acad Sci U S A (1993) 1.61
A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. J Gen Microbiol (1985) 1.53
The cytochemical localization of phospholipase in Candida albicans infecting the chick chorio-allantoic membrane. Sabouraudia (1977) 1.18
In vivo and in vitro toxicity of phospholipase C from Pseudomonas aeruginosa. Toxicon (1992) 1.07
Secreted phospholipases of the dimorphic fungus, Candida albicans; separation of three enzymes and some biological properties. Sabouraudia (1985) 1.01
FAB/mass spectrometry of lipids. Prog Lipid Res (1991) 0.96
Exogenous phospholipase C permeabilizes mammalian cells to proteins. Exp Cell Res (1988) 0.88
Aspergillus fumigatus: a possible relationship between spore size and virulence for mice. J Gen Microbiol (1977) 0.84
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 2.79
Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (2007) 2.49
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect (1993) 2.10
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
Fluconazole-resistant candidosis in an HIV cohort. AIDS (1994) 1.95
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J (2010) 1.87
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (1994) 1.82
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett (1995) 1.66
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. J Clin Microbiol (1996) 1.65
Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2002) 1.61
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Invasive infection due to penicillium species other than P. marneffei. J Infect (2002) 1.58
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis (2008) 1.57
Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim (2003) 1.53
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother (1993) 1.51
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Aspergillus fungemia: report of two cases and review. Clin Infect Dis (1995) 1.42
New and emerging treatments for fungal infections. J Antimicrob Chemother (2008) 1.42
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis (1991) 1.40
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Endemic mycoses: a treatment update. J Antimicrob Chemother (1999) 1.39
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res (2004) 1.36
Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect (2009) 1.32
Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother (1997) 1.32
Administering amphotericin B--a practical approach. J Antimicrob Chemother (1994) 1.32
Aspergillus wound infection following laparostomy. J Infect (1996) 1.31
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2008) 1.31
Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect (1999) 1.29
Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1987) 1.28
Molecular genetics in Aspergillus fumigatus. Curr Opin Microbiol (2000) 1.27
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol (2010) 1.26
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother (2006) 1.26
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect (1995) 1.23
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother (1998) 1.19
Post-operative aspergillosis. Clin Microbiol Infect (2006) 1.19
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy (2009) 1.18
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med (1995) 1.17
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother (1998) 1.14
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol (1997) 1.13
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother (1999) 1.12
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol (1997) 1.11
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother (2001) 1.10
Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol (1996) 1.10
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect (2001) 1.09
Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med (1990) 1.07
When to use fluconazole. Lancet (1995) 1.07
Skin rash after triple vaccine. Arch Dis Child (1987) 1.07
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother (2001) 1.06
Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. Acta Physiol Scand (1983) 1.06
Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis (1990) 1.06
Excess mortality, length of stay and cost attributable to candidaemia. J Infect (2009) 1.04
Cross-sectional neurotoxicology study of lead-exposed cohort. J Toxicol Clin Toxicol (1989) 1.03
Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol (1997) 1.03
Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother (1994) 1.01
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis (2001) 1.00
Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis (1989) 1.00
Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. Thorax (1993) 1.00
In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother (1995) 0.99
Stroke: speech therapy. Community Outlook (1978) 0.99
HIV antigenaemia in acute HIV infection. Lancet (1987) 0.98
A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses (2001) 0.97
What can comparative genomics tell us about species concepts in the genus Aspergillus? Stud Mycol (2007) 0.96
Candida glabrata oesophagitis in a patient without HIV infection. Eur J Clin Microbiol Infect Dis (2000) 0.96
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob Agents Chemother (1996) 0.96
Isolation of Candida norvegensis from clinical specimens: four case reports. Clin Infect Dis (1996) 0.96
An algorithmic approach to aspergillus sinusitis. J Laryngol Otol (1994) 0.95
Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clin Microbiol Infect (2004) 0.95
Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. J Med Microbiol (1994) 0.95
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol (1998) 0.94
Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 0.94
In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother (2001) 0.94
Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis (2000) 0.93
High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J Antimicrob Chemother (2012) 0.92
Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2. J Clin Pathol (1993) 0.92
Neuralgic amyotrophy due to parvovirus infection. J Neurol Neurosurg Psychiatry (1987) 0.92
Voriconazole plasma monitoring. Arch Dis Child (2008) 0.92
The continuing challenge of acute and perforated appendicitis. Am J Surg (1976) 0.92
DNA typing of epidemiologically-related isolates of Aspergillus fumigatus. Epidemiol Infect (1995) 0.92
Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology (1984) 0.91